drugset / Trial / NCT05357898
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1/2, first-in-human, open label, multicenter study to assess safety and tolerability, antitumor activity, and immunogenic and pharmacodynamic effects of SQZ-eAPC-HPV as monotherapy and in combination with pembrolizumab in patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors. The study includes patients with head and neck, cervical, anal, vulvar, or penile cancer.
Timeline
- Start
- 2022-03-24
- Primary completion
- 2023-11-27
- Completion
- 2023-11-27
Outcome
Outcome not reported
Stopped: “Corporate Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Subject | SQZ-eAPC-HPV | Cell therapy | — | — |
Indications
No indication recorded.